HALOZYME THERAPEUTICS, INC. Lessee, Operating Lease, Liability, to be Paid, Year Three
HALOZYME THERAPEUTICS, INC. (HALO) had Lessee, Operating Lease, Liability, to be Paid, Year Three of $7.86 million as of 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Notes › Commitment and Contingencies › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree · last filed 2026-02-17
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year Three $7.86M.
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid, Year Three $6.19M.
- 2023-12-31: Lessee, Operating Lease, Liability, to be Paid, Year Three $5.68M.
- 2022-12-31: Lessee, Operating Lease, Liability, to be Paid, Year Three $5.46M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year Three |
|---|---|
| 2025-12-31 | $7.86M 10-K · filed 2026-02-17 |
| 2024-12-31 | $6.19M 10-K · filed 2025-02-18 |
| 2023-12-31 | $5.68M 10-K · filed 2024-02-20 |
| 2022-12-31 | $5.46M 10-K · filed 2023-02-21 |
| 2021-12-31 | $18.00K 10-K · filed 2022-02-22 |
| 2021-09-30 | $18.00K 10-Q · filed 2021-11-02 |
| 2021-06-30 | $18.00K 10-Q · filed 2021-08-09 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-10 |
| 2020-12-31 | $150.00K 10-K · filed 2021-02-23 |
| 2020-09-30 | $130.00K 10-Q · filed 2020-11-02 |
| 2020-06-30 | $2.69M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $2.68M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $1.56M 10-K · filed 2020-02-24 |
| 2019-09-30 | $2.86M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $2.56M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $2.56M 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |